förekomma. Om metastaserna är osteoblastis–
ka, ökar däremot PitP-koncentrationen (Kyl–
mälä et al., skall publiceras).
Tabell 3. Möjliga indikationer för ICTP-be–
stämning i serum
- metaboliska bensjukdomar
- osteolytiska benmetastaser
- reumatoid artrit
- multipel myelom
- kataboliska tillstånd (immobilisation m
fl)
LITTERATUR
l. Risteli L, Risteli J. Analysis of extracellular matrix prote–
ins in biological fluids [Översiktsartikel). Methods En–
zymoll987;145:381-411.
2. Risteli L, Risteli J. Noninvasive methods for detection of
organ fibrosis [Översiktsartikel]. I boken Connective
Tissue in Health and Disease (red. M Rojkind), CRC
Press, Boca Raton, 1990; 61-98.
3.Jensen LT, Olesen HP, Risteli J, Lorenzen
I.
Externa!
thoracic duct-venous shunt in conscious pigs for long–
term studies of connective tissue metabolites in lymph.
Lab Anim Sci 1990;40:620-4.
4. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook
CGD, Mowat AP. Serum concentrations of the type I
and III procollagen propeptides as biochemical markers
of growth velocity in healthy infants and children and in
children with disorders of growth. Pediatr Res 1991 (i
tryck)
5.Melkko J, Niemi S, Risteli L, Risteli J. Radioimmuno–
assay of the carboxyterminal propeptide of human type
I procollagen. Clin Chem 1990;36:1328-32.
6.Taubman MB, Goldberg B, Sherr CJ. Radioimmunoas–
say for human procollagen. Science 1974;186:1115-7.
7.Smedsmd B, Melkko J, Risteli L, Risteli J. Circulating
carboxyterminal propeptide of type I procollagen is
cleared mainly via the mannose receptor in liver en–
dothelial cells. Biochem J 1990;271:345-50.
8. Fleischmajer R, Perlish JS, Timpl R. Collagen fibrilloge–
nesis in human skin. Ann N Y Acad Sci USA
1985;460:246-57.
9.Niemelä O, Risteli L, Sotaniemi EA, Risteli J. Hetero–
geneity of antigens related to the aminoterminal propep–
tide of type III procollagen in human serum. Clin Chim
Acta 1982;124:39-44.
10.Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat AP,
Risteli
L.
Rapid equilibrium radioimmunoassay for the
amino-terminal propeptide of human type III procolla–
gen. Clin Chem 1988;34:715-8.
Il. Smedsmd B. Aminoterminal propeptide of type III pro–
collagen is cleared from the circulation by receptorme–
dialed endocytosis in liver endothelial cells. Collagen Re–
lat Res 1988;8:375-88.
8
12. Häckerstedt K, Risteli L, Salmela K, Risteli J. Serum ty–
pe III procollagen as a marker in liver transplantation.
Transplant Proc 1990;22:1574-5.
13. Bentsen KD, Hendriksen JH, Bendtsen F, H111rslev–
Petersen K, Lorenzen l. Splanchnic and rena! extraction
of circulating type III procollagen aminoterminal pro–
peptide in patients with normalliver function and in pa–
tients with alcoholic liver disease. Hepatology
1990;11:957-63.
14. Robins SP. Tumover and cross-Iinking of collagen [över–
siktsartikel). I boken Collagen in Health and Disease
(red. JB Weiss, MIV Jayson), Churchill Livingstone,
Edinburgh, 1982, s. 160-78.
15. Kivirikko Kl. Urinary excretion of hydroxyproline in
health and disease [översiktsartikel]. Int Rev Connect
Tissue Res 1970;5:93-163.
16. Charles P, Poser JW, Mosekilde L, Jensen FT. Estima–
tian of bone tumover evaluated by 47 Ca-kinetics. Effi–
ciency of serum bone gamma-carboxyglutamic acid–
containing protein, serum alkaline phosphatase, and
urinary hydroxyproline excretion. J Clin Invest
1985;76:2254-8.
17. Hartroann DJ, Trinchet J-C, Ricard-Blum S, Beaugrand
M, Callard P, Ville G. Radioimmunoassay of type I col–
lagen that mainly detects degradation products in se–
rum: application to patients with liver disease. Clin
Chem 1990;36:421-8.
18. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Pro–
collagen type I earboxy-terminal extension peptide in
serum as a marker of collagen biosynthesis in bone.
Correlation with iliac bone formation rates and compa–
rison with total alkaline phosphatase. J Bone Miner Res
1987;2:427-36.
19. Tapanainen P, Risteli L, Knip M, Käär M-L, Risteli J.
Serum aminoterminal propeptide of type III procolla–
gen: a potential predietar of the response to growth hor–
mone therapy. J Clin Endocrinol Metab 1988;67:1244-9.
20. Eriksson S, Zettervall O. The N-terminal propeptide of
collagen type III in serum as a prognostic indicator in
primary biliary cirrhosis. J Hepatol 1986;2:370-8.
21. McCullough AJ, Stassen WN, Wiesner RH, Czaja AJ.
Serial determinations of the amino-terminal peptide of
type III procollagen in severe chronic active hepatitis, J
Lab Clin Med 1987;109:55-61.
22. Hasselbalch H, Junker P, H111rslev-Petersen K, Lisse l,
Bentsen KD. Procollagen type III aminoterminal pep–
tide in serum in idiopathic myelofibrosis and allied con–
ditions: Relation to disease activity and effect of chemo–
therapy. Am J Hematol 1990;33:18-26.
23. Kauppila A, Puistola U, Risteli J, Risteli
L.
Aminoter–
minal propeptide of type III procollagen: A new prog–
nosis indicator in human ovarian cancer. Cancer Res
1989;49:1885-9.
24. Prockop
DJ,
Kivirikko Kl, Tuderman L, Guzman NA.
The biosynthesis of collagen and its disorders. N Engl
J
Med 1979;301:13-23,77-85.
Klinisk kemi
i
Norden 4, /99/
